NEW YORK (GenomeWeb News) – Contract research organization Apredica announced today that it has acquired the intellectual property and related assets of Cellumen for an undisclosed sum.
The acquisition provides Apredica with Cellumen's Cellular Systems Biology and high-content toxicology services and technologies. Specifically, Watertown, Mass.-based Apredica said that the deal will "significantly strengthen" the firm's high-content toxicology offerings.
Apredica is privately held and was founded in 2006 to provide contract testing services for evaluating and optimizing ADMET and pharmacokinetic properties of drug candidates in early-stage development. The firm said that it has 173 customers, with most in the US and others spread throughout the world.
"I am looking forward to leading the company's scientific growth into the in vitro toxicology market, where rapid scientific advances are now being made by pioneers in the field such as Cellumen," Apredica CEO Katya Tsaioun said in a statement. "Such technologies simultaneously improve our ability to detect mechanisms of human toxicity, reduce the time and cost of developing safe and efficacious drugs, and pave the way towards developing toxicology models that are more predictive of human biology than currently available models."